Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis

Drugs · Published 2026-05-13 · DOI 10.1007/s40265-026-02324-y

Free full text

Authors (2)

Jeffrey Lambe, Robert J. Fox

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Lambe, J., Fox, R. (2026). Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis. Drugs. https://doi.org/10.1007/s40265-026-02324-y

Related articles

• Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination · Inflammopharmacology · 2026 · Cites or is cited by this article
• Sibeprenlimab: First Approval · Drugs · 2026 · Same journal
• The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · Drugs · 2026 · Same journal
• Ecnoglutide: First Approvals · Drugs · 2026 · Same journal
• Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering · Drugs · 2026 · Same journal
• Etripamil: First Approval · Drugs · 2026 · Same journal
• Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · Drugs · 2026 · Same journal
• Emerging Cardiorenal Protective Therapies in Lupus Nephritis · Drugs · 2026 · Same journal
• Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors · Drugs · 2026 · Same journal
• Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here · Drugs · 2026 · Same journal